The U.S. Food and Drug Administration approved the use of Sanofi and Regeneron's blockbuster drug Dupixent for patients with ...

GLP-1s exploded seemingly out of nowhere, straining pharmacy plan bottom lines. Psoriasis treatments don't have to follow the ...

The FDA has approved the popular drug Dupixent (generic name, dupilumab) for adults and kids 12 and up with chronic spontaneous urticaria (CSU), a long-lasting itchy skin condition, when regular ...

The FDA had rejected the companies’ initial application in 2023, requesting additional data after the pharma firms reported ...

Medical research continues to progress in this field, with the development of a promising biologic drug Dupixent. Different kinds of eczema have unique presentations and treatment plans.

Patients undergoing treatment with Dupixent may experience notable adverse ... 6 months of age and older with moderate-to-severe eczema (atopic dermatitis or AD) that is not well controlled ...

AD is a growing market with an impressive pipeline of new products from current and future players in the field.

With the recent developments in the atopic dermatitis (AD) market, the field is becoming more competitive as novel therapies are soon anticipated to enter the market. This evolution may benefit AD ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...